{"analyses":[{"ciLowerLimit":"-4.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.79","groupDescription":"Stratification factors: Enrollment stage, PD-L1 status, Bajorin risk score/presence of liver metastases, and investigator choice of chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3761","paramType":"Difference in Event Free Rate","paramValue":"3.36","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.23","upperLimit":"59.88","value":"54.56"},{"groupId":"OG001","lowerLimit":"52.72","upperLimit":"63.10","value":"57.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"description":"Overall Survival (OS) Event Free Rate at 1 Year.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population includes only participants concurrently enrolled in Stage 2 and only those who had been randomized at the time of approval of Protocol WO30070 v6.","reportingStatus":"POSTED","timeFrame":"Year 1","title":"OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm","type":"SECONDARY","unitOfMeasure":"Percentage"}